Tech Center 1600 • Art Units: 1636
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17613216 | GENE EDITING IN DIVERSE BACTERIA | Non-Final OA | President and Fellows of Harvard College |
| 17593020 | HIGHLY MULTIPLEXED BASE EDITING | Final Rejection | President and Fellows of Harvard College |
| 17324383 | METHODS AND SYSTEMS FOR DETECTION OF KIDNEY DISEASE OR DISORDER BY GENE EXPRESSION ANALYSIS | Non-Final OA | The Regents of the University of California |
| 16005445 | CONDITIONAL GUIDE RNAs | Final Rejection | California Institute of Technology |
| 19317342 | SINGLE BASE SUBSTITUTION PROTEIN, AND COMPOSITION COMPRISING SAME | Non-Final OA | TOOLGEN INCORPORATED |
| 18287677 | PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 16616655 | ALTERED GUIDE RNAS FOR MODULATING CAS9 ACTIVITY AND METHODS OF USE | Non-Final OA | North Carolina State University |
| 18490880 | TRANSCRIPTIONAL PROGRAMMING IN A BACTEROIDES CONSORTIUM | Non-Final OA | Georgia Tech Research Corporation |
| 17286772 | ENGINEERED LONG INTERSPERSED ELEMENT (LINE) TRANSPOSONS AND METHODS OF USE | Final Rejection | Board of Regents, The University of Texas System |
| 17610360 | COMPOSITIONS AND METHODS FOR HOMOLOGY DIRECTED REPAIR | Final Rejection | Beth Israel Deaconess Medical Center, Inc. |
| 17290317 | Split CPF1 Protein | Final Rejection | The University of Tokyo |
| 18495741 | SUGAR-CONJUGATED LIPID NANOPARTICLES AND METHODS OF USE THEREFOR | Non-Final OA | University of Virginia Patent Foundation |
| 17552431 | ENGINEERED SSDNASE-FREE CRISPR ENDONUCLEASES | Non-Final OA | MONSANTO TECHNOLOGY LLC |
| 18043792 | SYSTEMS AND METHODS FOR CONTROLLING BACTERIAL TRANSCRIPTION | Non-Final OA | UNIVERSITY OF UTAH RESEARCH FOUNDATION |
| 17636750 | COMPOSITIONS AND METHODS FOR IDENTIFYING REGULATORS OF CELL TYPE FATE SPECIFICATION | Final Rejection | Duke University |
| 18969910 | Programmable Cleavage of RNA | Non-Final OA | New England Biolabs, Inc. |
| 18278255 | DNA APTAMERS AND COMPOSITIONS TARGETING ALPHA-SYNUCLEIN AND METHODS OF MAKING AND USING SAME | Non-Final OA | Qatar Foundation for Education, Science and Community Development |
| 18053696 | METABOLIC ENGINEERING OF CUPRIAVIDUS NECATOR FOR IMPROVED FORMATE UTILIZATION | Non-Final OA | Alliance for Sustainable Energy, LLC |
| 17162053 | COMPOSITIONS, SYSTEMS, AND METHODS FOR BASE DIVERSIFICATION | Non-Final OA | Pairwise Plants Services, Inc. |
| 17084721 | TYPE V CRISPR-CAS BASE EDITORS AND METHODS OF USE THEREOF | Non-Final OA | Pairwise Plants Services, Inc. |
| 18544882 | METHODS FOR THE IDENTIFICATION OF VARIANT RECOGNITION SITES FOR RARE-CUTTING ENGINEERED DOUBLE-STRAND-BREAK-INDUCING AGENTS AND COMPOSITIONS AND USES THEREOF | Non-Final OA | PIONEER HI-BRED INTERNATIONAL, INC. |
| 18753324 | NOVEL TYPE OF CRISPR/CAS SYSTEM | Non-Final OA | SNIPR BIOME APS |
| 18734772 | COMPOSITIONS AND METHODS FOR RNA SYNTHESIS | Non-Final OA | LineaRx, Inc. |
| 18415032 | Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four | Final Rejection | Intellia Therapeutics, Inc. |
| 17272005 | SCALABLE TAGGING OF ENDOGENOUS GENES BY HOMOLOGY-INDEPENDENT INTRON TARGETING | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17430669 | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE | Non-Final OA | BEAM THERAPEUTICS INC. |
| 17430289 | SPLICE ACCEPTOR SITE DISRUPTION OF A DISEASE-ASSOCIATED GENE USING ADENOSINE DEAMINASE BASE EDITORS, INCLUDING FOR THE TREATMENT OF GENETIC DISEASE | Final Rejection | BEAM THERAPEUTICS INC. |
| 17518209 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING AND TRANSLATION | Non-Final OA | Stoke Therapeutics, Inc. |
| 18455209 | METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERS | Non-Final OA | EARLI Inc. |
| 18278037 | Treatment of nerve damage using 5'UTR of Gpr151 gene or variant thereof | Non-Final OA | Daegu Gyeongbuk Institute of Science & Technology |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy